Physician profile
Lance E Tuetken
NPI 1992767792
$7,356.10
in general payments reported to CMS, 2019-2025
38 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $392 · 2021: $560 · 2022: $788 · 2023: $1,184 · 2024: $1,405 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,819.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,449.02 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $1,096.60 | 2019-2025 | |
| Novo Nordisk INC | $1,073.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $659.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $385.47 | 2021-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $351.85 | 2019-2025 | Xifaxan |
| Amgen INC. | $346.67 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $340.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.08 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $205.07 | 2019-2025 | Gardasil 9, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $113.59 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $106.97 | 2019-2022 | |
| Astellas Pharma US INC | $106.20 | 2019-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $105.30 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $90.62 | 2025 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Tuetken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.